Active surveillance for low-risk prostate cancer

Roberta Mazzucchelli, Ioannis Nesseris, Liang Cheng, Antonio Lopez-Beltran, Rodolfo Montironi, Marina Scarpelli

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Surgery, and radiation therapy remain the standard treatments for newly diagnosed prostate cancer patients. Nonetheless, these aggressive treatments are associated with decreased quality of life with altered sexual and urinary functions. Using modern risk stratification, several centers have gained significant experience in identifying patients with a low risk of prostate cancer progression and have adopted an active surveillance program with delayed, selective, or curative therapy. Interestingly, only limited numbers of patients under active surveillance require additional treatment. Recent data suggest that delayed treatment does not appear to alter the clinical outcome among those highly selected patients. A better understanding of the molecular determinants of prostate cancer behavior would not only enable healthcare professionals to identify which cases need aggressive treatment but, perhaps more importantly, would also indicate potential targets for the development of novel therapeutic strategies.

Original languageEnglish
Pages (from-to)3683-3692
Number of pages10
JournalAnticancer Research
Volume30
Issue number9
StatePublished - 2010

Fingerprint

Prostatic Neoplasms
Therapeutics
Radiotherapy
Quality of Life
Delivery of Health Care

Keywords

  • Active surveillance
  • Prostate cancer
  • Review
  • Watchful waiting

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Mazzucchelli, R., Nesseris, I., Cheng, L., Lopez-Beltran, A., Montironi, R., & Scarpelli, M. (2010). Active surveillance for low-risk prostate cancer. Anticancer Research, 30(9), 3683-3692.

Active surveillance for low-risk prostate cancer. / Mazzucchelli, Roberta; Nesseris, Ioannis; Cheng, Liang; Lopez-Beltran, Antonio; Montironi, Rodolfo; Scarpelli, Marina.

In: Anticancer Research, Vol. 30, No. 9, 2010, p. 3683-3692.

Research output: Contribution to journalArticle

Mazzucchelli, R, Nesseris, I, Cheng, L, Lopez-Beltran, A, Montironi, R & Scarpelli, M 2010, 'Active surveillance for low-risk prostate cancer', Anticancer Research, vol. 30, no. 9, pp. 3683-3692.
Mazzucchelli R, Nesseris I, Cheng L, Lopez-Beltran A, Montironi R, Scarpelli M. Active surveillance for low-risk prostate cancer. Anticancer Research. 2010;30(9):3683-3692.
Mazzucchelli, Roberta ; Nesseris, Ioannis ; Cheng, Liang ; Lopez-Beltran, Antonio ; Montironi, Rodolfo ; Scarpelli, Marina. / Active surveillance for low-risk prostate cancer. In: Anticancer Research. 2010 ; Vol. 30, No. 9. pp. 3683-3692.
@article{5f84150ebe0243e2a8ef4faf9ffb09ca,
title = "Active surveillance for low-risk prostate cancer",
abstract = "Surgery, and radiation therapy remain the standard treatments for newly diagnosed prostate cancer patients. Nonetheless, these aggressive treatments are associated with decreased quality of life with altered sexual and urinary functions. Using modern risk stratification, several centers have gained significant experience in identifying patients with a low risk of prostate cancer progression and have adopted an active surveillance program with delayed, selective, or curative therapy. Interestingly, only limited numbers of patients under active surveillance require additional treatment. Recent data suggest that delayed treatment does not appear to alter the clinical outcome among those highly selected patients. A better understanding of the molecular determinants of prostate cancer behavior would not only enable healthcare professionals to identify which cases need aggressive treatment but, perhaps more importantly, would also indicate potential targets for the development of novel therapeutic strategies.",
keywords = "Active surveillance, Prostate cancer, Review, Watchful waiting",
author = "Roberta Mazzucchelli and Ioannis Nesseris and Liang Cheng and Antonio Lopez-Beltran and Rodolfo Montironi and Marina Scarpelli",
year = "2010",
language = "English",
volume = "30",
pages = "3683--3692",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "9",

}

TY - JOUR

T1 - Active surveillance for low-risk prostate cancer

AU - Mazzucchelli, Roberta

AU - Nesseris, Ioannis

AU - Cheng, Liang

AU - Lopez-Beltran, Antonio

AU - Montironi, Rodolfo

AU - Scarpelli, Marina

PY - 2010

Y1 - 2010

N2 - Surgery, and radiation therapy remain the standard treatments for newly diagnosed prostate cancer patients. Nonetheless, these aggressive treatments are associated with decreased quality of life with altered sexual and urinary functions. Using modern risk stratification, several centers have gained significant experience in identifying patients with a low risk of prostate cancer progression and have adopted an active surveillance program with delayed, selective, or curative therapy. Interestingly, only limited numbers of patients under active surveillance require additional treatment. Recent data suggest that delayed treatment does not appear to alter the clinical outcome among those highly selected patients. A better understanding of the molecular determinants of prostate cancer behavior would not only enable healthcare professionals to identify which cases need aggressive treatment but, perhaps more importantly, would also indicate potential targets for the development of novel therapeutic strategies.

AB - Surgery, and radiation therapy remain the standard treatments for newly diagnosed prostate cancer patients. Nonetheless, these aggressive treatments are associated with decreased quality of life with altered sexual and urinary functions. Using modern risk stratification, several centers have gained significant experience in identifying patients with a low risk of prostate cancer progression and have adopted an active surveillance program with delayed, selective, or curative therapy. Interestingly, only limited numbers of patients under active surveillance require additional treatment. Recent data suggest that delayed treatment does not appear to alter the clinical outcome among those highly selected patients. A better understanding of the molecular determinants of prostate cancer behavior would not only enable healthcare professionals to identify which cases need aggressive treatment but, perhaps more importantly, would also indicate potential targets for the development of novel therapeutic strategies.

KW - Active surveillance

KW - Prostate cancer

KW - Review

KW - Watchful waiting

UR - http://www.scopus.com/inward/record.url?scp=77958517538&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958517538&partnerID=8YFLogxK

M3 - Article

C2 - 20944154

AN - SCOPUS:77958517538

VL - 30

SP - 3683

EP - 3692

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 9

ER -